Drug Trial Radar · NCT06012695
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
79
Planned (sponsor's estimate)
Start
Aug 11, 2023
Primary completion
May 30, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Novelwise Pharmaceutical CorporationIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.
Conditions
- Malignant Neoplasm
- Malignant Neoplasm of Brain
Interventions
NBM-BMX CapsuleDrug
Each capsule contains 100 mg of the active ingredient.
TemozolomideDrug
TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
Standard radiotherapyRadiation
A total dose of 60 Gy will be administered in 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Arm A, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose levelTime frame: up to 28 days
- [Arm B, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose levelTime frame: up to 10 weeks
- [Arm B, Phase II] Progression-free survival rate at 6 months (PFS6)Time frame: up to 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Not yet recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan · Recruiting
Linkou Chang-Gung Memorial Hospital
Taoyuan City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.